Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Cardiovascular Systems (CSII) stocks in Canada
Learn how to easily invest in Cardiovascular Systems stocks.
Cardiovascular Systems is a medical devices business based in the US. Cardiovascular Systems stocks (CSII.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.74 – a decrease of 2.07% over the previous week. Cardiovascular Systems employs 780 staff and has a trailing 12-month revenue of around $244.7 million.
How to buy stocks in Cardiovascular Systems
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CSII – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Cardiovascular Systems?
- Has coronavirus impacted Cardiovascular Systems shares?
- Cardiovascular Systems shares summary
- Compare share dealing platforms
- Is Cardiovascular Systems stock a buy or sell?
- Cardiovascular Systems performance over time
- Are Cardiovascular Systems shares over-valued?
- Cardiovascular Systems's financials
- How volatile are Cardiovascular Systems shares?
- Does Cardiovascular Systems pay a dividend?
- Have Cardiovascular Systems shares ever split?
- Other common questions
Cardiovascular Systems stock price (NASDAQ:CSII)Use our graph to track the performance of CSII stocks over time.
Cardiovascular Systems shares at a glance
|Latest market close||$15.61|
|52-week range||$14.12 - $44.57|
|50-day moving average||$19.65|
|200-day moving average||$24.98|
|Wall St. target price||$22.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.84|
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Cardiovascular Systems stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cardiovascular Systems price performance over time
|1 week (2022-05-11)||N/A|
|1 month (2022-04-20)||-28.53%|
|3 months (2022-02-18)||-17.06%|
|6 months (2021-11-22)||-34.77%|
|1 year (2021-05-21)||-59.49%|
|2 years (2020-05-22)||-57.82%|
|3 years (2019-05-22)||39.64|
|5 years (2017-05-22)||31.61|
Is Cardiovascular Systems under- or over-valued?
Valuing Cardiovascular Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cardiovascular Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cardiovascular Systems's PEG ratio
Cardiovascular Systems's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 177.27. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cardiovascular Systems's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Cardiovascular Systems's EBITDA
Cardiovascular Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 million.
The EBITDA is a measure of a Cardiovascular Systems's overall financial performance and is widely used to measure a its profitability.
Cardiovascular Systems financials
|Revenue TTM||$244.7 million|
|Gross profit TTM||$197.8 million|
|Return on assets TTM||-5.82%|
|Return on equity TTM||-12.42%|
|Market capitalisation||$601.2 million|
TTM: trailing 12 months
Cardiovascular Systems share dividends
We're not expecting Cardiovascular Systems to pay a dividend over the next 12 months.
Have Cardiovascular Systems's shares ever split?
Cardiovascular Systems's shares were split on a 1:10 basis on 26 February 2009. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiovascular Systems shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cardiovascular Systems shares which in turn could have impacted Cardiovascular Systems's share price.
Cardiovascular Systems share price volatility
Over the last 12 months, Cardiovascular Systems's shares have ranged in value from as little as $14.12 up to $44.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiovascular Systems's is 0.9054. This would suggest that Cardiovascular Systems's shares are less volatile than average (for this exchange).
Cardiovascular Systems overview
Cardiovascular Systems, Inc. , a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc.
Stocks similar to Cardiovascular Systems
Cardiovascular Systems in the news
SEC filings reveal massive selling in media names, including Disney and Comcast
Cable companies to offer effectively free internet to low-income homes
Insiders Now Seeing Red With CSII At New 52-Week Low
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.Read more…
More guides on Finder
Apps like Wealthsimple
Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
How to buy Entain stock in Canada
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
How to buy Kambi Group stock in Canada
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Best brokerage signup bonuses in 2022
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
How to buy Rush Street Interactive stock in Canada
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
How to buy PointsBet stock in Canada
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
How to buy Hanover Bancorp, Inc. (HNVR) stock in Canada when it goes public
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
How to buy PrimeBlock stock in Canada when it goes public
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
How to buy Actelis Networks (ASNS) stock in Canada when it goes public
Everything we know about the Actelis Networks IPO, plus information on how to buy in.